Daré Bioscience, Inc., a healthcare company based in San Diego, specializes in developing and commercializing pharmaceuticals for women's reproductive health, including products like XACIATO for bacterial vaginosis. The company, which launched its IPO in 2014, has a range of products in development, such as Ovaprene, a hormone-free contraceptive, and Sildenafil Cream for female sexual arousal disorder.
Dare Bioscience (DARE) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Dare Bioscience's actual EPS was -$0.88, missing the estimate of $0.00 per share, resulting in a -100.00% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!